Alvaro Gomez‐Ferrer

Alvaro Gomez‐Ferrer

Auto-generated profile, based on publicly available information

Alvaro Gomez‐Ferrer

Fundación IVO Valencia Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2018 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
ABAngel BORQUE-FERNANDO
Angel BORQUE-FERNANDO
JRJosé Rubio-Briones
José Rubio-Briones
Luis Mariano EstebanLuis Mariano Esteban
Luis Mariano Esteban
YDYan Dong
Yan Dong
ACAna Calatrava
Ana Calatrava
DODavid Okrongly
David Okrongly

1 June 2017 in Actas Urológicas Españolas (English Edition)
Verified
Journal Article
Closed access
JRJ. Rubio-Briones
J. Rubio-Briones
JCJ. Casanova
J. Casanova
FMFernando Martinez
Fernando Martinez
JDJ.L. Domínguez-Escrig
J.L. Domínguez-Escrig
AFAntonio Fernández
Antonio Fernández
JLJosé Antonio López-Guerrero
José Antonio López-Guerrero

1 April 2023 in Future Oncology
Verified
Journal Article
Open access
JCJoan Carles
Joan Carles
RMRafael Antonio Medina-Lopez
Rafael Antonio Medina-Lopez
JPJavier Puente
Javier Puente
ÁGÁlvaro Gómez-Ferrer
Álvaro Gómez-Ferrer
JNJavier Casas Nebra
Javier Casas Nebra
KFKarim Fizazi
Karim Fizazi
Aim: Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes in Spanish participants in ARAMIS. Patients & methods: Pa... Plain language summary Reduced risk of cancer spreading in Spanish patients with nonmetastatic castration-resistant prostate cancer treated with darolutamide in the global ARAMIS study Darolutamide... Tweetable abstract For Spanish patients with nmCRPC in ARAMIS, darolutamide increased metastasis-free survival and PSA response versus placebo. Adverse event incidence was similar in both arms. Out... Graphical abstract

31 December 2008 in Advances in Urology
Verified
Journal Article
Open access
PDF file
JBJose Rubio Briones
Jose Rubio Briones
ASArgimiro Collado Serra
Argimiro Collado Serra
ALAlvaro Gómez-Ferrer Lozano
Alvaro Gómez-Ferrer Lozano
JRJuan Casanova Ramón-Borja
Juan Casanova Ramón-Borja
IJInmaculada Iborra Juan
Inmaculada Iborra Juan
ENEduardo Solsona Narbón
Eduardo Solsona Narbón
High-intensity focused ultrasound (HIFU) competes with radiofrequency and cryotherapy for the treatment of small renal masses as a third option among ablative approaches. As an emerging technique, its possible percutaneous or laparoscopic application, low discomfort to the patient and the absence of complications make this technology attractive for the management of small renal masses. This manuscript will focus on the principles, basic research and clinical applications of HIFU in small renal masses, reviewing the present literature. Therapeutic results are controversial and from an clinical view, HIFU must be considered a technique under investigation at present time. Further research is needed to settle its real indications in the management of small renal masses; maybe technical improvements will certainly facilitate its use in the management of small renal masses in the near future.

1 June 2021 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
EAE. Polo Alonso
E. Polo Alonso
MBMiguel Ramírez Backhaus
Miguel Ramírez Backhaus
GWG. Wei
G. Wei
JMJ.M. Mascarós
J.M. Mascarós
FRF. Aragón Rodríguez
F. Aragón Rodríguez
JRJ. Rubio-Briones
J. Rubio-Briones

19 June 2026 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
ASArgimiro Collado Serra
Argimiro Collado Serra
LFLuís Resel Folkersma
Luís Resel Folkersma
ARAntonio Romero
Antonio Romero
MMMARIA RIAZA MONTES
MARIA RIAZA MONTES
AWAugusto Wong
Augusto Wong
AGAlvaro Gomez‐Ferrer
Alvaro Gomez‐Ferrer